The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
Open accessAbstract
Purpose: To gain insight into the prevalence and severity of chemotherapy-induced neuropathy and its influence on health-related quality of life (HRQOL) in a population-based sample of colorectal cancer (CRC) survivors 2 to 11 years after diagnosis. Methods: All alive individuals diagnosed with CRC between 2000 and 2009 as registered by the Dutch population-based Eindhoven Cancer Registry were eligible for participation. Eighty-three percent (n = 1,643) of patients filled out the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 and the EORTC QLQ Chemotherapy-Induced Peripheral Neuropathy 20. Results: The five neuropathy subscale–related symptoms that bothered patients with CRC the most during the past week were erectile problems (42% of men), trouble hearing (11%), trouble opening jars or bottles (11%), tingling toes/feet (10%), and trouble walking stairs or standing up (9%). Additionally, patients who received oxaliplatin more often reported tingling (29% v 8%; P = .001), numbness (17% v 5%; P = .005), and aching or burning pain (13% v 6%; P = .03) in toes/feet compared with those not treated with chemotherapy. They also more often reported tingling toes/feet (29% v 14%; P = .0127) compared with those treated with chemotherapy without oxaliplatin. Those with many neuropathy symptoms (eg, upper 10%) reported statistically significant and clinically relevant worse HRQOL scores on all EORTC QLQ-C30 subscales (all P < .01). Conclusion: Two to 11 years after diagnosis of CRC, neuropathy-related symptoms are still reported, especially sensory symptoms in the lower extremities among those treated with oxaliplatin. Because neuropathy symptoms have a negative influence on HRQOL, these should be screened for and alleviated. Future studies should focus on prevention and relief of chemotherapy-induced neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 2×
“5 standard deviation indicates a threshold of discriminant change.(26) In addition, multivariate linear regression models were used to investigate the association between sociodemographic and clinical characteristics with the EORTC QLQ-CIPN20 subscales and the most important single questions of the sensory scale.”
BackgroundMethodFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 2×
“However, a significant proportion of patients experience chronic neuropathy, which is mainly sensory.(5,8,9) An Australian study reported that neuropathy persisted in 79% of patients after a median follow-up of 29 months.”
BackgroundOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Babyak, M. A. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000127692.23278.a9 · Cited by 2,061
Sangha, O., Stucki, G., Liang, M. H., Fossel, A. H., & Katz, J. N. (2003) · Arthritis Care & Research · doi:10.1002/art.10993 · Cited by 1,806
International Union against Cancer
(1959) · Journal of the Faculty of Radiologists · doi:10.1016/s0368-2242(59)80060-9 · Cited by 1,220
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0107 · Cited by 658
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.012 · Cited by 583
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003) · Drugs · doi:10.2165/00003495-200363150-00003 · Cited by 456
Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.010 · Cited by 408
van de Poll-Franse, L. V., Horevoorts, N., Eenbergen, M. V., Denollet, J., Roukema, J. A., Aaronson, N. K., Vingerhoets, A., Coebergh, J. W., de Vries, J., Essink-Bot, M.-L., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.034 · Cited by 398
Self-citationVincent, A., Lahr, B. D., Wolfe, F., Clauw, D. J., Whipple, M. O., Oh, T. H., Barton, D. L., & St. Sauver, J. (2013) · Arthritis Care & Research · doi:10.1002/acr.21896 · Cited by 383
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds329 · Cited by 293
Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., & Bidoli, P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.008 · Cited by 274
Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
Pachman, D. R., Barton, D. L., Watson, J. C., & Loprinzi, C. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.115 · Cited by 268
Oxaliplatin-Associated Neuropathy: A Review
Cersosimo, R. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e319 · Cited by 268
Land, S. R., Kopec, J. A., Cecchini, R. S., Ganz, P. A., Wieand, H. S., Colangelo, L. H., Murphy, K., Kuebler, J. P., Seay, T. E., Needles, B. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6652 · Cited by 239
Background Noise: The Experience of Chemotherapy-Induced Peripheral Neuropathy
Bakitas, M. A. (2007) · Nursing Research · doi:10.1097/01.nnr.0000289503.22414.79 · Cited by 212
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy
Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., & Aaronson, N. K. (1998) · Annals of Oncology · doi:10.1023/a:1008344507482 · Cited by 207
Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
Park, S. B., Lin, C. S. Y., Krishnan, A. V., Goldstein, D., Friedlander, M. L., & Kiernan, M. C. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0248 · Cited by 198
Patient Perceptions Associated With Chemotherapy-Induced Peripheral Neuropathy
Tofthagen, C. (2010) · Clinical Journal of Oncology Nursing · doi:10.1188/10.cjon.e22-e28 · Cited by 176
Jansen, L., Herrmann, A., Stegmaier, C., Singer, S., Brenner, H., & Arndt, V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4013 · Cited by 170
Chemotherapy-Induced Peripheral Neuropathy: NURSING PERSPECTIVES
Visovsky, C. (2003) · Cancer Investigation · doi:10.1081/cnv-120018236 · Cited by 166
A validation study of the domains of the core EORTC Quality of Life Questionnaire
Niezgoda, H. E., & Pater, J. L. (1993) · Quality of Life Research · doi:10.1007/bf00449426 · Cited by 165
Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
Beijers, A. J. M., Jongen, J. L. M., & Vreugdenhil, G. (2012) · PubMed · Cited by 139
Self-citationChemotherapy-Induced Peripheral Neuropathy: A Review and Implications for Oncology Nursing Practice
Wickham, R. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.361-376 · Cited by 134
Wolf, S. L., Barton, D. L., Qin, R., Wos, E. J., Sloan, J. A., Liu, H., Aaronson, N. K., Satele, D., Mattar, B. I., Green, N. B., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1141-9 · Cited by 132
Lemmens, V. E. P. P., van Steenbergen, L. N., Janssen-Heijnen, M. L. G., Martijn, H., Rutten, H. J. T., & Coebergh, J. W. W. (2010) · Acta Oncologica · doi:10.3109/02841861003733713 · Cited by 131
Self-citationPeripheral Neuropathy in Patients With Colorectal Cancer Receiving Oxaliplatin
Tofthagen, C., McAllister, R. D., & McMillan, S. C. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.cjon.182-188 · Cited by 78
Thong, M. S. Y., Mols, F., Lemmens, V. E. P. P., Rutten, H. J. T., Roukema, J. A., Martijn, H., & van de Poll-Franse, L. V. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.030 · Cited by 70
Self-citationChemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma
Kim, B., Park, H.-R., Roh, H., Jeong, D., Kim, B. S., Park, K. W., Cho, S. C., So, Y. T., Oh, S. Y., & Kim, S. J. (2010) · Quality of Life Research · doi:10.1007/s11136-010-9670-0 · Cited by 52
Thong, M. S. Y., Mols, F., Lemmens, V. E. P. P., Creemers, G., Slooter, G. D., & van de Poll-Franse, L. V. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.006 · Cited by 52
Self-citationMost colorectal cancer survivors live a large proportion of their remaining life in good health
Soerjomataram, I., Thong, M. S. Y., Ezzati, M., Lamont, E. B., Nusselder, W. J., & van de Poll-Franse, L. V. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0010-2 · Cited by 40
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C. E., Knox, C., Shapiro, C. L., Gilman, P. B., & Cancer and Leukemia Group B (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.cra9013 · Cited by 15
Smith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C. E., Knox, C., Shapiro, C. L., Gilman, P. B., & Cancer and Leukemia Group B (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.cra9013 · Cited by 11
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
American Cancer Society Colorectal Cancer Survivorship Care Guidelines
El‐Shami, K., Oeffinger, K. C., Erb, N. L., Willis, A., Bretsch, J. K., Pratt‐Chapman, M. L., Cannady, R. S., Wong, S. L., Rose, J., Barbour, A. L., et al. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21286 · Cited by 475
Papamichael, D., Audisio, R. A., Glimelius, B., de Gramont, A., Glynne-Jones, R., Haller, D., Köhne, C.-H., Rostoft, S., Lemmens, V., Mitry, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 471
Self-citationEURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
van de Velde, C. J. H., Boelens, P. G., Borras, J. M., Coebergh, J.-W., Cervantes, A., Blomqvist, L., Beets-Tan, R. G. H., van den Broek, C. B. M., Brown, G., Van Cutsem, E., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.048 · Cited by 404
Mols, F., Beijers, T., Vreugdenhil, G., & van de Poll-Franse, L. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2255-7 · Cited by 374
Self-citation
Metadata
- Authors
- Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-20
- Volume
- 31
- Issue
- 21
- Pages
- 2699-2707
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142831070
- Cited by
- 359
- References
- 39
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.